Every piece MicroCap Desk has published on Theriva Biologics, newest first. Independent editorial — we take no compensation from the companies we cover.
Spain's AEMPS cleared Theriva's VIRAGE2 trial to test more frequent VCN-01 dosing in pancreatic cancer.
Phase 2b oncolytic-virus data at AACR. But the balance sheet is what actually moves the equity — cash runway analysis and three financing paths.
Sentiment labels reflect the Desk's directional view at the time each article was published and are not price targets, ratings, or investment advice. Microcap securities carry a high risk of loss. See our full Disclosure.